Compare ConocoPhillips (COP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Pfizer Inc — how do they compare? ConocoPhillips trades at $134.1 (market cap $161.21B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: ConocoPhillips and Pfizer Inc are close in size by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Pfizer Inc for 158 Days on average.
| COP | PFE | |
|---|---|---|
Market Cap | $161.21B | $158.56B |
Volume | 6,058,403 | 44,138,282 |
Sector | Energy | Health |
52-Week High | $141.22 | $29.02 |
52-Week Low | $85.66 | $23.67 |
Typical Hold Time | 79 Days | 158 Days |
Enterprise Value | $176.81B | $210.06B |
Dividend Yield | 2.5% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.35% with strong technical momentum. The stock shows robust fundamentals with a P/E of 17.75, net income margin of 14.65%, and consistent earnings beats in recent quarters. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and the UK. Technical indicators show bullish moving averages with the stock trading near pivot point resistance at $134.
COP presents a compelling investment case with strong analyst support (75% buy rating) and a $154.75 price target offering 15% upside. However, investors face risks from oil price volatility, geopolitical tensions affecting international operations, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The company's solid cash flow generation and strategic LNG expansion provide growth catalysts.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
